HIV health state (with or without opportunistic infection). DTG was compared to efavirenz (EFV), raltegravir (RAL), darunavir/ritonavir, rilpivirine (RPV), elvitegravir/cobicistat, atazanavir/ritonavir and lopinavir/ritonavir in TN patients and to RAL in TE patients. The initial cohort, the main efficacy data and safety data were derived from phase III clinical trials.
Treatment algorithms were based on expert opinion. Costs normalized to the year 2013 included antiretroviral treatment cost, testing, adverse event, HIV and cardiovascular disease care and were derived from the literature. 
INTRODUCTION
The human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system and is characterized by a decline in CD4?
cell count and immune function, which can result in life-threatening opportunistic infections (OI), HIV-related cancer and acquired immunodeficiency syndrome (AIDS). HIV represents a global pandemic affecting an estimated 34 million individuals and causing 1.7 million deaths through AIDS or HIV-related illness per year [1] . Currently, there is no cure and, consequently, the aim of antiretroviral (ARV) drugs is to control disease progression through long-term inhibition of HIV replication. During the last 25 years, six new classes of drugs targeting different viral replication mechanisms have emerged, allowing the introduction of new antiretroviral therapies (ARTs) [2] . The use of a combination of three or four ARTs, known as highly active antiretroviral therapy, has resulted in the gradual evolution of HIV from an acute fatal disease into a chronic condition [3] .
However, there remains a need for ARTs that can sustain maximal virological suppression and maintain excellent tolerability profiles without compromising on efficacy or protection against the development of resistance. Dolutegravir (DTG), an integrase inhibitor (INI), was developed to meet this need and was approved in Canada in October 2013. TIVICAY Ò (ViiV Healthcare, Research Triangle Park, NC, USA), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and children 12 [11] , which had been based on the cost-effectiveness of preventing AIDS complications (CEPAC) model [12] . In addition to updating model inputs to reflect the changing nature of HIV, ARAMIS-DTG included revised treatment algorithms for TN and TE patients, explicitly considered AEs, and explored the link between lipid levels and the risk of cardiovascular disease (CVD) [13] .
METHODS

Model Structure
ARAMIS-DTG adopted a microsimulation approach, following individual patients transitioning through mutually exclusive health states using a monthly cycle length time. The probability of disease progression was continuously adjusted on individual patient characteristics and the occurrence of events such as virological failure, OI and/or AEs ( Fig. 1 Depending on the treatment received, patients faced a probability of experiencing virological suppression (defined as viral load suppression below 50 copies/mL at 48 weeks).
Virological suppression led to an increase in the overall CD4? cell count, which continued to increase as long as patients remained virologically suppressed up to 5 years on successful ART with a maximum possible value of 1200 cells/lL. A steep increase during the first 2 months was assumed, with a slower rate of increase considered afterwards according to clinical trial evidence [14, 15] . The rate of CD4? cell recovery was assumed to be treatment specific and based on clinical trial results.
If patients were not virologically suppressed, they would move on to the next treatment regimen following a treatment algorithm derived for each of the comparators on the basis of an advisory board of Canadian HIV clinical experts. Treatment selection was based on the previous treatment and the resistance status (Supplementary Appendix 3).
After moving to the next treatment regimen, patients would then face a probability of experiencing virological suppression under the new regimen. After failing a number of treatments, patients were assumed to have exhausted treatment options, which resulted in a decrease in the CD4? cell count using natural history data and an approach detailed in previously published CE models [16] . In this approach, the CD4? cell count decline contingent on viral load observed in an untreated population from the Multicenter AIDS Cohort Study [17] was corrected using findings from the Swiss HIV Cohort, which showed that no CD4? cell count decrease was observed for treated patients with log 10 viral loads of four [18] .
In addition to the virological suppression rate derived from trials and the consequent CD4? cell count increase/decrease, the monthly rate of viral rebound after initial viral suppression (commonly known as ''late failure rate'') was considered from the second year based on long-term evidence from clinical trials [14, [19] [20] [21] [22] [23] [24] [25] .
The ARAMIS-DTG model allowed up to six HO-13-13512. 2013) [28] . This was applied to account for the fact that HIV patients are expected to have an increased risk of death from other causes related or not to different risk
The main model outcomes were (1) 
Model Inputs
All the data sources used for the model (global and local sources) are summarized in Table 1 .
Efficacy Parameters
The efficacy data applied to the TN and TE models are presented in Supplementary [8] .
Where data were unavailable after 1 year for comparators, identical efficacy was considered for DTG and the comparator, and identical efficacy parameters were applied to each subsequent regimen, with values obtained from various sources of published clinical evidence and validated by clinical experts.
After the trial period, evidence from the STARTMRK trial (ClinicalTrials.gov # NCT00369941) was used for all treatments to inform the late failure rate and CD4? cell count increase of patients who maintained virological suppression on their initial treatment [19] . 
Costs of ART
Utilities
Utilities applied to each CD4? cell count strata were derived from a study by Isogai et al. [39] , which examined the relationship between Health Utility Index-3-derived health preference score and HIV health status measured by CD4? cell count ( Table 2) . Disutilities applied to patients developing CVD were derived from Franks et al. [36] and applied using a multiplicative relationship. Disutilities associated with AEs and OIs were not considered in the base case but were explored in sensitivity analyses using published evidence [37, 38] (Table 2) .
Sensitivity Analyses
The 
RESULTS
HIV-1 TN Patients
Base Case
In the TN analysis, DTG was found to be the dominant strategy (i.e., more clinically effective and cost saving) compared with all other treatments considered ( 
Sensitivity Analyses
These results appear to be fairly robust to variations in any of the model inputs in sensitivity analyses, which contributed to increased confidence in the base case estimates. The only sensitivity analysis under which DTG stopped being dominant was the use of generic EFV ? Truvada instead of Atripla.
In any case, for this analysis, DTG was still within the range normally considered costeffective with an ICER of Can$44,604/QALY gained (Supplementary Appendix 5-7).
HIV-1 TE Patients
Base Case
For the TE model, DTG was also the dominant strategy over RAL ( 
Sensitivity Analyses
Again, these results in the TE analysis were robust to variations in any of the model inputs in sensitivity analyses, which contributed to increased confidence in the base case estimates.
DTG remained dominant in all scenarios, including the use of a discounted price for RAL (Can$23/day). The sole exception to dominance occurred with the elimination of the discount rate (for costs and effects), but the estimated ICER (Can$11,787) is well within the range for a drug to be considered cost-effective ( Supplementary Appendix 8) .
DISCUSSION
This analysis demonstrates that, in the perspective of the publicly funded healthcare system, DTG is more effective and less costly in [44, [47] [48] [49] .
Two validation exercises were conducted with ARAMIS-DTG to assess the convergent validity of ARAMIS related to the modeling of long-term outcomes of HIV and to assess its real-life predictive power. Firstly, a corroboration exercise between ARAMIS-DTG and CEPAC was conducted using published CEPAC study data [42] 
